NIHR Alert: Spironolactone is not an effective treatment for patients with atrial fibrillation and preserved ejection fraction, research shows

Expert commentary is provided for IMPRESS-AF trial (n=250), in which spironolactone did not improve exercise capacity, heart function, or quality of life in these patients. In fact, the treatment significantly worsened kidney function.

Source:

NIHR Dissemination Centre